Incidence of serious upper gastrointestinal bleeding in patients taking non-steroidal anti-inflammatory drugs in Japan

Acta Medica Okayama

Volumn 62, Issue 1, 2008, Pages 29-36

  Ishikawa, Shigenao ^a   Inaba, Tomoki ^a   Mizuno, Motowo ^b   Okada, Hiroyuki ^c   Kuwaki, Kenji ^c   Kuzume, Toshiaki ^a   Yokota, Hitomi ^a   Fukuda, Yasuyo ^a   Takeda, Kou ^a   Nagano, Hiroshi ^a   Wato, Masaki ^a   Kawai, Kozo ^a  

^a KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b HIROSHIMA CITY HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Hemorrhage; Non steroidal anti inflammatory drugs; Peptic ulcer; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DUODENUM ULCER; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; JAPAN; MALE; MEDICAL RECORD; MIDDLE AGED; PEPTIC ULCER BLEEDING; STOMACH ULCER;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COHORT STUDIES; DUODENAL ULCER; FEMALE; FOLLOW-UP STUDIES; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; JAPAN; MALE; MEDICAL RECORDS; MIDDLE AGED; PEPTIC ULCER HEMORRHAGE; PROTON PUMP INHIBITORS; STOMACH ULCER;

EID: 41549111201     PISSN: 0386300X     EISSN: 0386300X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Singh G and Triadafilopoulos G: Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl (1999) 56: 18-24.
2. Tsokos M and Schmoldt A: Contribution of nonsteroidal anti-inflammatory drugs to deaths associated with peptic ulcer disease: a prospective toxicological analysis of autopsy blood samples. Arch Pathol Lab Med (2001) 125: 1572-1574.
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK and Schnitzer TJ; VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 343: 1520-1528.
4. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A and Hawkey CJ; TARGET Study Group: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet (2004) 364: 665-674.
5. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ and Yeomans ND: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med (1998) 338: 727-734.
6. Pilotto A, Franceschi M, Leandro G, Paris F, Cascavilla L, Longo MG, Niro V, Andriulli A, Scarcelli C and Di Mario F: Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther (2004) 20: 1091-1097.
7. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, Mann SG, Simon TJ, Sturrock RD and Russell RI: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med (1996) 334: 1435-1439.
8. Graham DY, Agrawal NM and Roth SH: Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet (1988) 2: 1277-1280.
9. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM and Geis GS: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1995) 123: 241-249.
10. Kohler B and Riemann JF: Upper Gl-bleeding - value and consequences of emergency endoscopy and endoscopic treatment. Hepatogastroenterology (1991) 38: 198-200.
11. Marchildon PA, Ciota LM, Zamaniyan FZ, Peacock JS and Graham DY: Evaluation of three commercial enzyme immunoassays compared with the 13C urea breath test for detection of Helicobacter pylori infection. J Clin Microbiol (1996) 34: 1147-1152.
12. Kawai T, Kawakami K, Kudo T, Ogiahara S, Handa Y and Moriyasu F: A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication. Intern Med (2002) 41: 780-783.
13. Kauffman G: Aspirin-induced gastric mucosal injury: lessons learned from animal models. Gastroenterology (1989) 96: 606-614.
14. Physician's health study: aspirin and primary prevention of coronary heart disease. N Engl J Med (1989) 321: 1825-1828.
15. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H and Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (1998) 351: 1755-1762.
16. Serrano P, Lanas A, Arroyo MT and Ferreira IJ: Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther (2002) 16: 1945-1953.
17. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP and Colin-Jones DG: Risk of bleeding peptic ulcer associated with non-steroidal anti-inflammatory drugs. Lancet (1994) 343: 1075-1078.
18. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD and Wiholm BE: Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol (2002) 54: 320-326.
19. Taha AS, Angerson WJ, Knill-Jones RP and Blatchford O: Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther (2005) 22: 285-289.
20. Topol EJ and Falk GW: A coxib a day won't keep the doctor away. Lancet (2004) 364: 639-640.
21. Ahlawat SK, Richard Locke G, Weaver AL, Farmer SA, Yawn BP and Talley NJ: Dyspepsia consulters and patterns of management: a population-based study. Aliment Pharmacol Ther (2005) 22: 251-259.
22. Ishizaki T and Horai Y: Cytochrome P450 and the metabolism of proton pump inhibitors: Emphasis on rabeprazole. Aliment Pharmacol Ther (1999) 13: 27-36.
23. Nakashima S, Arai S, Mizuno Y, Yoshino K, Ando S, Nakamura Y, Sugawara K, Koike M, Saito E, Naito M, Nakao M, Ito H, Hamaoka K, Rai F, Asakura Y, Akamatu M, Fujimori K, Inao M, Imai Y, Ota S, Fujiwara K and Shiibashi M: A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther (2005) 21: 60-66.
24. Huang JQ, Sridhar S and Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet (2002) 359: 14-22.
25. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, Chan HL and Sung JJ: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med (2001) 344: 967-973.
26. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, Wason CM, Peacock RA and Gillon KR: Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet (1998) 352: 1016-1021.
27. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H and Shiratori Y: The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol (2005) 100: 1037-1042.
28. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N and Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med (2001) 345: 784-789.